Download presentation
Presentation is loading. Please wait.
Published bySofia Mikkelsen Modified over 5 years ago
1
Supporting Realistic Medicine through the delivery of a Single National Formulary
2
Welcome
3
Today’s session In this interactive session, delegates will take part in group discussions to consider how to implement the new approach throughout Scotland by considering current practice and what will help facilitate the roll- out of the national formulary and how it can be embedded.
4
Realistic Medicine and the development of the Scottish Formulary
5
What is Realistic Medicine?
6
Aims of Realistic Medicine
7
Benefits of the Scottish Formulary
Support the reduction of unwarranted variation in prescribing practice, reducing medicine harm and continuing to improve patient outcomes. Help to achieve more equitable, greater value-based care so that the potential population benefit from medicines can be maximised. Supports the principle that services and functions of the health service which can be delivered more efficiently at national level will be done on a ‘Once for Scotland’ basis
8
Current position 11
9
Defining the Scottish Formulary
How do the existing formularies describe themselves? “list of medicines approved for local use” “promoting high quality, safe and cost-effective prescribing” “evidence-based formulary ” “drug prescribing guidance” “provide appropriate treatment for the vast majority of patients” “a tool to assist” “based on local expert opinion and practice” “primary and secondary care”
10
Business As Usual Arrangements
Development approach Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter Business As Usual Arrangements Development Process Chapter Groups Evidence & Guidance Analysis Data Platform IT Comms & Engagement SMC Decisions Appeals Process
11
Development process 1. Preparation 2. Development 3. Peer Review
4. Completion
12
A consultant’s perspective on the Scottish Formulary
13
A national approach to realising realistic medicine in antimicrobial prescribing
Dr R. Andrew Seaton Consultant in Infectious Diseases, NHS GGC Chair of the Scottish Antimicrobial Prescribing Group @raseaton66
14
SAPG INDIVIDUAL POPULATION CONSORTIUM OF EXPERTS/HB AMTs
Delivering a National Antimicrobial Stewardship Programme INDIVIDUAL POPULATION OPTIMISE USE AND OUTCOME CONSORTIUM OF EXPERTS/HB AMTs ANTIMICROBIAL PRESCRIBING SURVEILLANCE QUALITY IMPROVEMENT EDUCATION
15
ANTIMICROBIAL PRESCRIBING
SAPG NATIONAL FORMULARY CONSENSUS GUIDELINES REDUCE VARIATION REDUCE HARM (AMR+) & OPTIMISE OUTCOME ANTIMICROBIAL PRESCRIBING OPTIMISE USE AND OUTCOME UNNECESSARY OR REDUNDANT REDUCE WASTE AMR, CDI, SAB GaV PEN ALLERGY REDUCE HARM PERSONALISE/ INDIVIDUALISE RISK-BASED DECISION SUPPORT VIA MOBILE APP.
16
SAPG: Reducing Variation and Waste
17
SAPG: Reducing Harm VoL outbreak
18
Delivering a National Antimicrobial Stewardship
SAPG Delivering a National Antimicrobial Stewardship Programme NATIONAL FORMULARY CONSENSUS GUIDELINES REDUCE VARIATION REDUCE HARM (AMR+) & OPTIMISE OUTCOME ANTIMICROBIAL PRESCRIBING OPTIMISE USE AND OUTCOME UNNECESSARY OR REDUNDANT REDUCE WASTE AMR, CDI, SAB GaV PEN ALLERGY REDUCE HARM PERSONALISE/ INDIVIDUALISE RISK-BASED DECISION SUPPORT VIA MOBILE APP.
19
Advantages of a Single National Approach – Antimicrobial Perspective
SAPG - National engagement and process for change In line with SAPG work to date Reducing harm, waste and unnecessary variation through consensus “Working across borders” during training Amplifying best practice Avoiding duplication of effort
20
Challenges of a Single National Approach – Antimicrobial Perspective
Local autonomy and cross speciality consensus Local initiatives to enhance AMS Contingency/flexibility/response To supply issues To outbreaks To new evidence Governance of “Business as usual” Local responsibility for guidance
21
% commonality BNF Chapter – Formulary is not the same as guidance
NHS Board Range 96% - 97% 67% - 78% 49% - 91% Formulary is not the same as guidance (or practice) Effective Prescribing &
22
Primary Care 80% of antimicrobials are prescribed within PC
PHE guidance agreed/adopted by SAPG and AMTs De facto national consensus
23
Secondary Care SAPG guidance Variation in empirical guidance
Principles of AMS Surgical Prophylaxis Gent and Vanc guidance Variation in empirical guidance Evolved over time Reviewed annually/2yearly by HB AMTs
25
Promotion of Gentamicin-based
Empirical Hospital Guidance (Sepsis)
26
Preservation of our most valued agents
AMTs
27
Guideline survey May 2017 NHS HB UNDIFFERENTIATED SEPSIS GGC Gent Amox
+/- Fluclox Lothian Met Lanarkshire +/-Met Grampian +/- Met Tayside Forth Valley Co-amox Borders Dumfries Met +/- Fluclox Highland Fife Ayr and Arran Fluclox +/-Met
28
Guideline survey June 2018 NHS HB UNDIFFERENTIATED SEPSIS GGC Gent
Amox +/- Fluclox Lothian Met +/- Fluclox Lanarkshire Met Grampian +/- Met Tayside Forth Valley Borders Dumfries Highland Fife Ayr and Arran Fluclox +/-Met
29
STEWARDSHIP INITIATIVES - Learning from variation to generate change
30
Guideline survey June 2018 NHS HB UROSEPSIS GGC Gent Amox Lothian
Lanarkshire Grampian Tayside Forth Valley Borders Dumfries Highland Fife Ayr and Arran
31
Guideline survey June 2018 NHS HB CONSENSUS INTRA-ABDOMINAL SEPSIS
CNS INFECTION SEVERE CAP ASP PNEUMONIA NON-SEVERE HAP SEVERE HAP IECOPD LOWER UTI NON SEVERE CELLULITIS SEVERE CELLULITIS
32
Other considerations in national guidance in antimicrobial prescribing
Restricted/Protected status of antimicrobials: Consensus Duration of therapy: Some minimal variation IV to Oral Switch Therapy (IVOST): Work ongoing Approach to penicillin allergy: National work underway
33
Penicillin Allergy De-labelling
10% of inpatients “labelled” Mislabelling in c. 80% + associated with increased Rx cost, admission length, AMR and poorer outcomes Teicoplanin 17 xs increased risk of anaphylaxis cf other antibiotics De-labelling complicated
34
Single (Scottish) National Formulary Infections Chapter
Phase 1: Primary care (80% of antibiotic prescribing) – SAPG/AMTs Are we there already? HIV (HIV leads group, Rak Nandwani) HCV (National group, John Dillon) Phase 2: Hospital prescribing – SAPG/AMTs
35
Conclusions SAPG provides a national framework for AMS
Excellent engagement with board AMTs Work programme is aligned to Realistic Medicine Consensus in best prescribing practice in both primary and secondary care is fundamental to reducing waste, harm and unnecessary variation in practice Good progress to date towards these goals Needs flexibility and ability to respond to emerging challenges
36
Acknowledgements SAPG SNF Group
Health Boards Busi Mooka (Tay) , Ursula Altmeyer (A&A), Anne Duguid (Borders), Bryan Marshall (D&G), Niketa Platt (Fife), Robbie Weir (FV), Sandy Mackenzie (Gramp), Brian Jones (GGC), Gail Haddock (Highland), Adam Brown (Highland), Stephanie Dundas (Lanark), Morgan Evans (Lothian), Professional Groups: Anne Thomson (National Prescribing Adviser group), Suzanne Clark (Public Partner), Mairi MacLeod (SMVN) Jacqueline Sneddon (SAPG) and Deirdre O’Driscoll (IPCN),
37
A GP’s perspective on the Scottish Formulary
45
Group discussions
46
19 20 21 18 17 14 15 16 22 23 28 29 30 27 26 24 25 12 13 4 5 2 1 End 6 3 10 7 9 11 8 Group discussions Time remaining: People Promotion Processes Patients Minutes Which roles within your Board should we be directly communicating with regarding the implementation of the Scottish Formulary? (prioritise your suggestions) Which communication methods should be utilised when engaging with Board colleagues around implementation? (prioritise your suggestions) Which existing processes within your Board should we be considering as part of the implementation plans? (consider what happens now and what processes you feel will change when the Scottish Formulary is introduced) What do you feel are the key points to be considered in communications with patients around the Scottish Formulary? (prioritise your suggestions)
47
Feedback from group discussions
48
Thank you for your contribution Keep up to date at: http://www
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.